EYES2022 ESE Young Endocrinologists and Scientists (EYES) 2022 Calcium and Bone (10 abstracts)
Bone metabolism and dual-release Hydrocortisone: results from a real-life study
Ferrari D 1 , Sada V 1 , Hasenmajer V 1 , De Alcubierre D 1 , Puliani G. 1 , 2 , Minnetti M 1 , Cozzolino A 1 , Tomaselli A 1 , Pofi R 1 , Lenzi A 1 & Isidori A 1
1Sapienza University of Roma, Experimental Medicine; 2Regina Elena National Cancer Institute, Oncological Endocrinology Unit, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS)
Background: Patients with adrenal insufficiency (AI) require long-term glucocorticoid (GC) replacement therapy and generally show an increased prevalence of bone metabolism alterations. Only few data are available on bone safety of dual-release Hydrocortisone (DR-HC) therapy.
Objective: To evaluate bone metabolism in primary AI (PAI) and secondary AI (SAI) during long-term therapy with DR-HC.
Methods: We evaluated patients with AI on immediate-release GC therapy, collecting data on bone turnover markers, femoral and lumbar spine bone mineral density (BMD) and trabecular bone score (TBS) before and up to 60 months after the switch to an equivalent dose of DR-HC.
Results: 28 patients (15 PAI and 13 SAI, mean age 51±14 years, 15 females, 8 post-menopausal) were included. Mean duration of AI was 95 months (range 12-432). Any other hormonal disorders (i.e. diabetes, hypothyroidism, hypogonadism, GH deficiency) were adequately controlled throughout the study. All patients had normal calcium and phosphorus levels and most were under cholecalciferol therapy (mean Vit D 26 ng/mL at baseline; 95% CI 18 – 33 ng/mL). No patient was under anti-resorptive therapy. At baseline, 18% of patients had BMD values compatible with osteopenia and 11% had a diagnosis of osteoporosis. Compared to baseline, no significant difference was observed in BMD at femur neck, total hip and total lumbar spine at 24 (P = .293;P = .471;P = .820), 36 (P = .812;P = .322;P = .890), 48 (P = .820;P = .925;P = .432) and 60 months (P = .450;P = .792;P = .847) of DR-HC therapy. Similarly, TBS values did not significantly change after 24 (P = .945), 36 (P = .400), 48 (P = .582) and 60 months (P = .572). Alkaline phosphatase, C-terminal telopeptide and osteocalcin levels showed no difference in all timepoints (at 60 months:P = .730;P = .412;P = .981).
Conclusions: DR-HC is a safe treatment option in terms of bone health in patients with AI, maintaining stable bone mass, bone quality and bone turnover despite aging.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more